Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 3:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 88 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent Ovarian Serous Adenocarcinoma Clear all
Recruiting Phase 1 Interventional

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Clear Cell Adenocarcinoma, Chondrosarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Recurrent Ovarian High Grade Serous Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Melanoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
Interventions
Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel, Capivasertib
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 25, 2026, 3:20 PM EDT
Recruiting Phase 2 Interventional

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

NCT05231122
View directory record Official record
Conditions
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
Interventions
Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Buffalo, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 25, 2026, 3:20 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Ribociclib and Letrozole Treatment in Ovarian Cancer

NCT03673124
View directory record Official record
Conditions
Low Grade Serous Carcinoma
Interventions
Ribociclib, Letrozole
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
27
States / cities
San Francisco, California • Gainesville, Florida • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jun 25, 2026, 3:20 PM EDT
Terminated Phase 3 Interventional

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

NCT00002819
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, cyclophosphamide, mitoxantrone hydrochloride, paclitaxel, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Up to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
64
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT02111941
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm, Fallopian Tube Serous Neoplasm, Fallopian Tube Transitional Cell Carcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions
Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jun 25, 2026, 3:20 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

NCT04034927
View directory record Official record
Conditions
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
20
States / cities
Orange, California • Aurora, Colorado • Hartford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 1 Interventional

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03586661
View directory record Official record
Conditions
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Progressive Disease, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Copanlisib, Niraparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Results available

Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00408590
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
carcinoembryonic antigen-expressing measles virus, oncolytic measles virus encoding thyroidal sodium iodide symporter, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis
Biological · Genetic · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 1 Interventional

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT03552471
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Serous Carcinoma, Recurrent Uterine Carcinosarcoma, Platinum Resistant Ovarian Cancer
Interventions
Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study, Rucaparib Camsylate
Other · Biological · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Jun 25, 2026, 3:20 PM EDT
Terminated Phase 1 Interventional

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

NCT03924245
View directory record Official record
Conditions
Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Entinostat, Olaparib
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Kansas City, Kansas • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

NCT00002600
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2001
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Jun 25, 2026, 3:20 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

NCT02502266
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Cediranib, Cediranib Maleate, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Questionnaire Administration, Topotecan, Topotecan Hydrochloride
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
370
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 2 Interventional Results available

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT02283658
View directory record Official record
Conditions
Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions
Everolimus, Laboratory Biomarker Analysis, Letrozole
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Jun 25, 2026, 3:20 PM EDT
Terminated Phase 2 Interventional Results available

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02923739
View directory record Official record
Conditions
Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Biological · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Voorhees Township, New Jersey • Dallas, Texas • Houston, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Jun 25, 2026, 3:20 PM EDT
Active, not recruiting Phase 1 Interventional

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

NCT02208375
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, High Grade Ovarian Serous Adenocarcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Uterine Corpus Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Capivasertib, Laboratory Biomarker Analysis, Olaparib, Pharmacological Study, Vistusertib
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Results available

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

NCT02898207
View directory record Official record
Conditions
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Breast Carcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Triple-Negative Breast Carcinoma, Refractory Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Serous Adenocarcinoma, Refractory Primary Peritoneal Serous Adenocarcinoma, Refractory Triple-Negative Breast Carcinoma, Unresectable High Grade Fallopian Tube Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Primary Peritoneal Serous Adenocarcinoma
Interventions
Olaparib, Onalespib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Jun 25, 2026, 3:20 PM EDT
Active, not recruiting Phase 1 Interventional

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

NCT04092270
View directory record Official record
Conditions
Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 25, 2026, 3:20 PM EDT
Active, not recruiting Phase 2 Interventional

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

NCT06494150
View directory record Official record
Conditions
Low Grade Ovarian Serous Adenocarcinoma
Interventions
nab-Sirolimus, Fulvestrant
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 1 Interventional

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

NCT00066651
View directory record Official record
Conditions
Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
Interventions
SS1(dsFv)-PE38 immunotoxin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Jun 25, 2026, 3:20 PM EDT
Terminated Phase 1 Interventional

A Study to Investigate LYL797 in Adults With Solid Tumors

NCT05274451
View directory record Official record
Conditions
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
Interventions
LYL797
Biological
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 1 Interventional

Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00003967
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
etoposide, topotecan hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Iowa City, Iowa • Baltimore, Maryland • Camden, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Jun 25, 2026, 3:20 PM EDT
Completed Phase 1 Interventional

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

NCT00357448
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
denileukin diftitox, intraperitoneal administration, laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry
Biological · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Jun 25, 2026, 3:20 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer

NCT00354601
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
capecitabine, docetaxel
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Jun 25, 2026, 3:20 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

NCT02068794
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection, Chest Radiography, Single Photon Tomography and Computed Tomography Scan, Computed Tomography, Magnetic Resonance Imaging
Other · Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jun 25, 2026, 3:20 PM EDT